Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.44 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.44 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.44 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.44 |
| ▸ | PRKCA | P17252 | 3/20 | 0.44 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
| ▸ | DGKA | P23743 | 2/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2728683 | 1.00 | LMNA (0.50) | LMNAMAPTMEN1KMT2AKDM4E | |
| SCHEMBL10275408 | 0.92 | DGKA (0.56) | MAPTENPP2LPAR6LPAR1LPAR4 | |
| SCHEMBL8087624 | 0.79 | MAPK1 (0.49) | LMNAMAPTMEN1KMT2AKDM4E | |
| Glycerin SCHEMBL2718540 | 0.76 | KDM4E (0.59) | LMNAMAPTMEN1KMT2AKDM4E | |
| SCHEMBL2782421 | 0.76 | MAPT (0.46) | LMNAMAPTMEN1KMT2AKDM4E | |
| SCHEMBL25870 | 0.76 | MAPT (0.46) | LMNAMAPTMEN1KMT2AKDM4E | |
| SCHEMBL2783097 | 0.76 | MAPT (0.46) | LMNAMAPTMEN1KMT2AKDM4E | |
| SCHEMBL19019979 | 0.76 | MEN1 (0.43) | LMNAMAPTMEN1KMT2AKDM4E | |
| SCHEMBL669205 | 0.74 | DGKA (0.57) | LMNAMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL11026247 | 0.74 | DGKA (0.57) | LMNAMAPTMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136537-A1 | Lipopeptide compositions and methods of use therof | VAXINNATE CORPORATION | 2009-05-28 | — | — | US | claimed |
| WO-2007078879-A2 | LIPOPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | VAXINNATE CORPORATION (US) | 2007-07-12 | — | — | WO | claimed |
| US-20190142744-A1 | NUCLEIC ACID NANOCAGES, COMPOSITIONS, AND USES THEREOF | NORTH CAROLINA STATE UNIVERSITY | 2019-05-16 | — | — | US | disclosed |
| WO-2017027592-A1 | NUCLEIC ACID NANOCAGES, COMPOSITIONS, AND USES THEREOF | NORTH CAROLINA STATE UNIVERSITY (US) | 2017-02-16 | — | — | WO | disclosed |
| US-20160067190-A1 | INJECTABLE NANO-NETWORK GELS FOR DIABETES TREATMENT | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2016-03-10 | — | — | US | disclosed |
| EP-2991673-A1 | INJECTABLE NANO-NETWORK GELS FOR DIABETES TREATMENT | Massachusetts Institute of Technology (US) | 2016-03-09 | — | — | EP | disclosed |
| WO-2014179344-A1 | INJECTABLE NANO-NETWORK GELS FOR DIABETES TREATMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-11-06 | — | — | WO | disclosed |
| US-20090136537-A1 | Lipopeptide compositions and methods of use therof | VAXINNATE CORPORATION | 2009-05-28 | — | — | US | disclosed |
| WO-2007078879-A2 | LIPOPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | VAXINNATE CORPORATION (US) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067190-A1 | INJECTABLE NANO-NETWORK GELS FOR DIABETES TREATMENT | SLC2A3, IDE, IAPP | LMNA 3351/4885MAPT 3176/4885MEN1 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.